Abstract
The effects of the putative selective dopamine D-1 antagonist benzazepine SCH 23390 and of the selective dopamine D-2 antagonist Ro22-2586 on stereotypy induced by the selective D-2 agonist RU24213 were compared. RU24213 (0.5–15 mg/kg) dose-dependently induced stereotyped behaviour characterised by continuous downward sniffing and locomotion. These responses were antagonised, as expected, by 40–200 μg/kg Ro22-2586, but surprisingly blocked by 40–200 μg/kg SCH 23390. The selectivities of these compounds for dopamine receptor subtypes were verified in terms of their relative abilities to displace the in vitro binding of 3H-piflutixol to striatal D-1 receptors and of 3H-spiperone to D-2 receptors. As SCH 23390 fails to influence D-2 mediated prolactin secretion or emesis in vivo, there appears to be no significant formation of an active metabolite of SCH 23390 with D-2 antagonist activity. Because SCH 23390 has some affinity for 5-hydroxytryptamine receptors, any effect on the serotonergic behavioural syndrome induced by 10 mg/kg 5-methoxy-N,N-dimethyltryptamine was also studied. The serotonergic responses of hind limb abduction, reciprocal forepaw treading and Straub tail were unaltered after 40–200 μg/kg SCH 23390, indicating no significant 5-HT blockade or non-specific depressant action at these doses which might influence the expression of stereotypy. Thus, these data are consistent with blockade of tonic D-1 dopaminergic activity that may influence the expression of behaviours initiated byD-2 dopaminergic stimulation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Christensen AV, Arnt J, Hyttel J, Larsen J-J, Svendsen O (1984) Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci 34:1529–1540
Creese I, Sibley DR, Hamblin MW, Leff SE (1983) The classification of dopamine receptors: relationship to radioligand binding. Ann Rev Neurosci 6:43–71
Cross AJ, Mashal RD, Johnson JA, Owen F (1983) Preferential inhibition of ligand binding to calf striatal dopamine D-1 receptors by SCH 23390. Neuropharmacology 22:1327–1329
Davidson AB, Boff E, MacNeil DA, Wanger J, Cook L (1983) Pharmacological effects of Ro22-1319: a new antipsychotic agent. Psychopharmacology 79:32–39
Euvrard C, Ferland L, Di Paulo T, Beaulieu M, Labrie F, Oberlander C, Raynaud JP, Bossier JR (1980) Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels. Neuropharmacology 19:379–386
Fray PJ, Sahakian BJ, Robbins TW, Koob GF, Iversen SD (1980) An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine. Psychopharmacology 69:253–259
Hicks PE, Shoemaker H, Langer SZ (1984) 5-HT receptor antagonist properties of SCH 23390 in vascular or smooth muscle and brain. Eur J Pharmacol 105:339–342
Hilditch A, Drew GM, Naylor RJ (1984) SCH 23390 is a very potent and selective antagonist at vascular dopamine receptors. Eur J Pharmacol 97:333–334
Hyttel J (1983) SCH 23390-the first selective dopamine D-1 antagonist. Eur J Pharmacol 91:153–154
Iorio LC, Barnett A, Leitz FH, Houser VP, Kordoba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226:462–468
Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 227:93–96
Laduron PM (1984) Criteria for receptor sites in binding studies. Biochem Pharmacol 33:833–839
Leysen JE, Gommeren W (1981) Optimal conditions for 3H-apomorphine binding and anomalous equilibrium binding of 3H-apomorphine and 3H-spiperone to rat striatal membranes: involvement of surface phenomena versus multiple binding sites. J Neurochem 36:201–219
Mailman RB, Schulz DW, Lewis MH, Staples L, Rollema H, De Haven DL (1984) SCH 23390: a selective D-1 dopamine antagonist with potent D-2 behavioral actions. Eur J Pharmacol 101:159–160
Molloy AG, Waddington JL (1984) Dopaminergic behaviour stereospecifically promoted by the D-1 agonist R-SK & F 38393 and selectively blocked by the D-1 antagonist SCH 23390. Psychopharmacology 82:409–410
Molloy AG, Waddington JL (1985) Sniffing, rearing and locomotor responses to the D-1 dopamine agonist R-SK&F 38393 and to apomorphine: differential interactions with the selective D-1 and D-2 antagonists SCH 23390 and metoclopramide. Eur J Pharmacol 108:305–308
O'Boyle KM, Waddington JL (1984) Selective and stereospecific interactions of R-SK&F 38393 with 3H-piflutixol but not 3H-spiperone binding to striatal D-1 and D-2 dopamine receptors: comparisons with SCH 23390. Eur J Pharmacol 98:433–436
O'Boyle KM, Molloy AG, Waddington JL (1985) Benzazepine derivatives: nature of the selective and stereospecific interactions of SK&F 38393 and SCH 23390 with brain D-1 receptors. In: Woodruff GN (ed) Dopamine systems and their regulation. MacMillan Press, London (in press)
Olson GL, Cheung H-C, Morgan KD, Blount JF, Todaro L, Berger L, Davidson AB, Boff E (1981) A dopamine receptor model and its application in the design of a new class of rigid pyrrolo (2,3-g) isoquinoline antipsychotics. J Med Chem 24:1026–1034
Plantje JF, Daus FJ, Hansen HA, Stoof JC (1984) SCH 23390 blocks D-1 and D-2 dopamine receptors in rat neostriatum in vitro. Naunyn-Schiedeberg's Arch Pharmacol 327:180–182
Robbins TW, Sahakian BJ (1981) Behavioural and neurochemical determinants of drug-induced stereotypy. In: Rose FC (ed) Metabolic disorders of the nervous system. Pitman, London, pp 245–291
Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32:229–313
Sloviter RS, Drust EG, Connor JD (1978) Specificity of a rat behavioral model for serotonin receptor activation. J Pharmacol Exp Ther 206:339–347
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pugh, M.T., O'Boyle, K.M., Molloy, A.G. et al. Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU24213. Psychopharmacology 87, 308–312 (1985). https://doi.org/10.1007/BF00432713
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00432713